Medicines Co. (MDCO) Misses Q2 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Buy The Medicines Company (MDCO) on Weakness, Guggenheim Says
July 29, 2015 11:25 AM EDTGuggenheim analyst Louise Chen is out defending The Medicines Company (NASDAQ: MDCO) amid today's weakness following the company's 2Q15 miss. Shares are down 5% to $31.84 currently.
Chen commented, "This was not surprising to us, since customers have held back on ordering Angiomax this year in anticipation of the launch of cheaper, generic versions of... More
